The effect of Esmolol before cardioplegia and as a combination in cardioplegia on biochemical markers of myocardial injury in patients undergoing coronary artery bypass graft surgery

The effect of Esmolol before cardioplegia and in the cardioplegic solution on the myocardial injury biomarkers in coronary artery bypass graft surgery patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180428039456N1

Enrollment

280

Registered

2019-07-26

Start date

2019-03-03

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary Artery disease. Atherosclerotic heart disease of native coronary artery

Interventions

Intervention 1: The intervention group receives esmolol hydrochloride (as 100 mg/10 ml vial, ESOCARD, SAMARTH life sciences PVT. LTD pharmaceutical Co. INDIA) during the operation. First, as a 2 mg/kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Only coronary bypass grafting surgery candidates due to coronary artery disease and atherosclerosis Left ventricular Ejection fraction between 45-60% Left ventricle end diastole Diameter (LVEDD) less than 60 mm Age above 18 years old Not having diabetes mellitus type 2 or consuming any oral hypoglycemic agents Not having severe systemic diseases (including any pulmonary, hepatic, renal, and musculoskeletal diseases or immune system illnesses) Not participating in any other studies Not having any confirmed arrhythmia or consuming any anti-arrhythmic agents (except beta-blockers)

Exclusion criteria

Exclusion criteria: Not willing to participate in the study No need for emergency operation No history of inappropriate reaction to Esmolol Not received Esmolol over the past 30 days

Design outcomes

Primary

Measure	Time frame
Average of cardiac biomarkers Troponin I, CK-MB and LDH. Timepoint: Measurement of biochemical markers of myocardial injury before and 4, 12, 24 and 48 hours after surgery. Method of measurement: Patient blood samples and laboratory measurements.	—

Secondary

Measure	Time frame
Frequency of ventricular fibrillation during the heart re-beat. Timepoint: After unclamping the aorta. Method of measurement: Electrocardiogram.;Hours of ICU stay. Timepoint: After the surgery. Method of measurement: hours documented in the charts.;Duration of patient admission after surgery in hospital. Timepoint: Number of hospital admission days in the post-operative. Method of measurement: Follow patient.;Need for inotropic drugs. Timepoint: Check the number of inotropes used. Method of measurement: Follow patient.	—

Measure

Time frame

Frequency of ventricular fibrillation during the heart re-beat. Timepoint: After unclamping the aorta. Method of measurement: Electrocardiogram.;Hours of ICU stay. Timepoint: After the surgery. Method of measurement: hours documented in the charts.;Duration of patient admission after surgery in hospital. Timepoint: Number of hospital admission days in the post-operative. Method of measurement: Follow patient.;Need for inotropic drugs. Timepoint: Check the number of inotropes used. Method of measurement: Follow patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehran Shahzamani

Esfahan University of Medical Sciences

drshahzamani@yahoo.com+98 31 3260 0961

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026